POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
Portfolio Pulse from
Kahn Swick & Foti, LLC is investigating the proposed sale of Poseida Therapeutics to Roche Holdings. Shareholders will receive $9.00 in cash plus a contingent value right for additional payments up to $4.00 per share.
November 27, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Poseida Therapeutics is under investigation by Kahn Swick & Foti, LLC regarding its proposed sale to Roche Holdings. The deal offers $9.00 per share in cash plus contingent value rights.
The investigation by Kahn Swick & Foti, LLC could impact the perception of the fairness of the deal, potentially affecting shareholder sentiment and the stock price. However, the terms of the deal are already set, which may limit immediate price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100